Scientific publications

A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.

Project Indication

Darolutamide

Prostate cancer

Scientific articles

Fizazi et al; N Engl J Med

 

14 February 2019

 

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

ODM-203

(targeted FGFR+VEGFR inhibitor)

Solid tumours

Congress posters

ESMO 2018

 

 

Cholangiocarcinoma Foundation Annual Conference 2017

 
ESMO 2016

 


ASCO 2016

 

 

Scientific articles

Holmström et al; Mol Can Ther 

 

19-23 October 2018

 

 

1-3 February 2017



7-11 October 2016

 


3-7 June 2016

 

 

 

9 October 2018
 

 

Phase 1/2 study of ODM-203, e selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors 

 

Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

 

ODM-203 a selective inhibitor of FGFR and VEGFR, shows strong anti-tumor activity, and induces anti-tumor immunity. Open access 

ODM-207

(BET protein inhibitor)

Cancer

  
   

Congress posters

ESMO 2018

 

 

AACR Annual Meeting 2018

 


2nd European Cancer Epigenetics

Conference 

 

AACR Annual Meeting 2017
 

 

19-23 October 2018

 

 

14-18 April 2018

 


11-13 May 2017

 

 

1-5 April 2017

 

ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer

 

Therapeutic targeting of estrogen receptor positive breast cancer with the BETbromodomain inhibitor ODM-207 

 

Targeting cancer with a novel BET bromodomain inhibitor

 



Targeting cancer with a novel BET bromodomain inhibitor

 

Immune-mediated anti-tumor activity with a clinical stage BET bromodomain inhibitor ODM-207 in pre-clinical models

ODM-208 

(CYP11A1 inhibitor)

Prostate cancer (CRPC)

     

Congress posters

ESMO 2018

 


ASCO GU 2018

 

 

The 24th Annual PCF Scientific Retreat

 

ESMO 2017

 

 

19-23 October 2018

 


8-10 February 2018

 


5-7 October 2017

 

8-12 September 2017

 

CYP11A1 inhibitor as a therapeutic approach for the treatment of castration resistant prostate cancer

 

CYP11A1 inhibitor as a threapeutic approach for the treatment of castration resistant prostate cancer

 

ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer

 

ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
 

ODM-104

(more effective COMT inhibitor)

Parkinson's disease

Congress posters

MDS 2018

 

 

EAN 2018

 

 

 

 

 

 

AAN 2018

 

 

5-9 October 2018

 

 

16-19 June 2018

 

 

 

 

 

 

21-27 April 2018

 

 

 ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subject

 

 Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ODM-104 a Novel Catechol-O-Methyltransferase Inhibitor, after Single Escalating Doses in Healthy Subjects

 

Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ODM-104 a Novel Catechol-O-Methyltransferase Inhibitor, after Escalating Repeated Doses in Healthy Subjects

 

ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects

 

ODM-109

(oral levosimendan)

ALS

Congress posters

ALS / MND 2018

 

 NEALS 2018

 

ALS / MND 2017

 

 

7-9 December 2018

 

2-4 October 2018

 

8-10 December 2017

 

 

 

Oral levosimendan in ALS: the REFALS phase 3 study design

 

Oral levosimendan in ALS: the REFALS phase 3 study design

 

 Scientific background for developing oral levosimendan (ODM-109) for the treatment of Amyotrophic Lateral Sclerosis

 

Oral levosimendan (ODM-109): Key placebo-controlled results from the phase 2 study in ALS patients with SVC between 60-90% predicted at screening